AEterna Zentaris (STU:ET80) Change In Payables And Accrued Expense : €0.50 Mil (TTM As of Mar. 2024)

View and export this data going back to 1995. Start your Free Trial

What is AEterna Zentaris Change In Payables And Accrued Expense?

AEterna Zentaris's Change In Payables And Accrued Expense for the quarter that ended in Mar. 2024 was €0.65 Mil. It means AEterna Zentaris's Accounts Payable & Accrued Expense increased by €0.65 Mil from Dec. 2023 to Mar. 2024 .

AEterna Zentaris's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2023 was €0.07 Mil. It means AEterna Zentaris's Accounts Payable & Accrued Expense increased by €0.07 Mil from Dec. 2022 to Dec. 2023 .

AEterna Zentaris Change In Payables And Accrued Expense Historical Data

The historical data trend for AEterna Zentaris's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AEterna Zentaris Change In Payables And Accrued Expense Chart

AEterna Zentaris Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

-0.72

0.37

0.47

1.02

0.07

AEterna Zentaris Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															0.22	-0.37	-0.15	0.37	0.65

AEterna Zentaris Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.50 Mil.

AEterna Zentaris Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of AEterna Zentaris's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

AEterna Zentaris (STU:ET80) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AEterna Zentaris Inc (STU:ET80) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

AEZS:USA AEZS:Canada

Address

222 Bay Street, Suite 3000, PO Box 53, c/o Norton Rose Fulbright Canada, LLP, Toronto, ON, CAN, M5K 1E7

Website

https://www.zentaris.com

AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland.

AEterna Zentaris (STU:ET80) Headlines

No Headlines